Robert Kamen Ph.D
Member of Board
Bob Kamen is Member of the Board of EpimAb Biotherapeutics.
He has more than 30 years of experience in the pharmaceutical and biotechnology industries. Bob currently serves as interim chief technology officer of Jounce Therapeutics and entrepreneur in residence at Third Rock Ventures. Previously he was the President of Abbott Bioresearch Center, where he oversaw the discovery and production of Humira®, the first fully human antibody to achieve marketing approval in the U.S. and Europe, and was a member of the Abbott Pharmaceuticals Executive Management Committee.
Bob also served as the President of BASF Bioresearch Corp., until it was acquired by Abbott Laboratories in 2001. Earlier in his career, Bob led discovery at Genetics Institute, Inc. In 2005, he co-founded BioAssets Development Corporation, a biotherapeutics company focusing on spinal diseases. Cephalon exercised its option to acquire BioAssets in 2010. Bob serves as a director of Harbour Antibodies BV, Lycera Corp. and Opsonic Therapeutics and advises other biopharmaceutical companies. Bob has an undergraduate degree in biophysics from Amherst College and a PhD in biochemistry and molecular biology from Harvard University.